Skip to content
OpenCapital
Get started

NeoGenomics NEO Self-pay — NET REVENUE

Other product segments

Client direct billing
$131.61M+7.8%
Commercial insurance
$30.94M+24.5%
Medicare and other government
$25.4M+16.8%

Similar metrics at other companies

GeneDx Holdings logo
WGSSelf-pay patients — Total Revenue
$286K+198%
Surgery Partners, Inc. logo
SGRYSelf-pay — Revenue
$19.2M-4.5%
ARD
ARDTSelf-pay and other — Net patient service revenue
$71.48M-11.7%
iRhythm Holdings, Inc. logo
IRTCNon-contracted third-party payors — Revenue, net
$11.04M+9.4%
iRhythm Holdings, Inc. logo
IRTCContracted third-party payors — Revenue, net
$106.8M+27.4%
Surgery Partners, Inc. logo
SGRYSelf-pay — Revenue by service type as a proportion of total revenues (percent)
2.4%-0.3pp

Other financials

Income statement

See full
Revenue$186.7M+11.1%
Gross profit$80.9M+10.4%
Operating income-$18.2M+34.4%
Net income-$17.1M+34.0%
EPS (diluted)-$0.13+35.0%

Balance sheet

See full
Cash & equivalents$146.1M-57.8%
Total debt$66.3M+5.3%
Total equity$828.8M-6.7%
Total assets$1.3B-15.9%

Cash flow

See full
Operating cash flow-$8.1M+67.9%
CapEx$5.0M+11.1%
Free cash flow-$13.1M+56.0%

Valuation

See full
Market cap$1.68B+86.5%
Enterprise value$1.6B+159%
P/S2.3×+0.9×

Profitability

See full
Gross margin43.2%-1.1pp
Operating margin-14.2%+1.1pp
Net margin-13.3%+2.4pp
FCF margin-4.9%—

Returns & leverage

See full
Return on equity-11.6%+6.2pp
Debt / equity0.1×0.0×
Current ratio4.4×+2.4×

Where this comes from

Reported directly by NeoGenomics in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.

The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about NeoGenomics's self-pay — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NeoGenomics's self-pay — NET REVENUE?
NeoGenomics (NEO) reported self-pay — NET REVENUE of -$17K in Q1 2026.
How has NeoGenomics's self-pay — NET REVENUE changed year-over-year?
NeoGenomics's self-pay — NET REVENUE decreased by 143.6% year-over-year, from $39K to -$17K.
What is the long-term trend for NeoGenomics's self-pay — NET REVENUE?
Over 3 years (2021 to 2024), NeoGenomics's self-pay — NET REVENUE has grown at a -4.1% compound annual growth rate (CAGR), from $772K to $681K.
What does self-pay — NET REVENUE mean?
This metric represents the total revenue generated from genetic and molecular testing services where the patient or individual is directly responsible for payment rather than a third-party insurer or healthcare provider. It serves as a measure of direct-to-consumer or out-of-pocket demand for specialized diagnostic services. Monitoring this revenue stream helps assess the company's ability to capture market share outside of traditional insurance-reimbursed channels.